LPM787000048

Luye Pharma announced on April 8 that the first subject has been enrolled in the Phase II clinical trial in China of LY03020, an oral controlled-release tablet the company describes as a dual agonist targeting both TAAR1 and the serotonin 2C receptor, with the filing categorized under China’s Class 1 innovative drug designation for schizophrenia. The announcement, filed as a voluntary disclosure with the Hong Kong Stock Exchange, confirmed enrollment initiation only. Study design, patient population size, dosing regimen, primary endpoints, and blinding status were not disclosed in the source document. No safety or efficacy findings are available at this stage. The LY03020 China trial follows earlier IND clearance in both China and the United States, according to Luye Pharma’s prior disclosures, though no ClinicalTrials.gov registration for this specific Phase II China study was identified at the time of writing. The data remain unavailable pending trial progression, and no DSMB or monitoring statements were included in the announcement. The enrolled patient population, disease severity criteria, and trial duration have not been stated publicly. LY03020 is described by Luye Pharma as a small molecule dual agonist of TAAR1 and 5-HT2CR — a mechanistic profile that, if confirmed in clinical evaluation, would distinguish it from approved antipsychotics acting primarily through dopamine D2 receptor antagonism, such as risperidone, or the TAAR1-selective agonist ulotaront, which Sunovion advanced into Phase III before discontinuing development in 2023. TAAR1 agonism has been explored as a non-dopaminergic approach to schizophrenia, with the potential to avoid some adverse effects associated with D2 blockade, though clinical validation remains limited. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website